文献速递造血干细胞移植与细胞治疗

巴利昔单抗治疗激素难治性急性移植物抗宿主病:真实世界分析

Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis.
PubMed 文献 · Am J Hematol · 2022-02-04

该真实世界研究纳入中国36家医院的940例激素难治性急性移植物抗宿主病(SR-aGVHD)患者,共给予3683剂巴利昔单抗。巴利昔单抗治疗后第28天总体缓解率(ORR)为79.4%(95%CI 76.5%-82.3%),3年非复发死亡率和总生存率分别为26.8%(95%CI 24.0%-29.6%)和64.3%(95%CI 61.2%-67.4%)。倾向性评分匹配显示联合治疗未提高ORR,反而较单药治疗增加感染率。

要点

  • 巴利昔单抗治疗SR-aGVHD第28天ORR为79.4%(95%CI 76.5%-82.3%)。
  • 联合治疗较单药治疗未提高ORR,且感染率增加。
  • 联合治疗、III-IV级aGVHD及巴利昔单抗治疗前高危改良明尼苏达aGVHD风险评分与治疗反应独立相关。

核心结论

  • 真实世界数据提示巴利昔单抗治疗SR-aGVHD安全有效。

研究设计与样本

  • 真实世界分析,纳入中国36家医院的940例SR-aGVHD患者,共给予3683剂巴利昔单抗。
  • 巴利昔单抗单药治疗642例,联合其他二线治疗298例。
  • 采用1:1倾向性评分匹配比较单药与联合治疗的疗效和安全性。

主要发现

  • 巴利昔单抗治疗后第28天ORR累积发生率为79.4%(95%CI 76.5%-82.3%)。
  • 巴利昔单抗治疗后3年非复发死亡率为26.8%(95%CI 24.0%-29.6%),总生存率为64.3%(95%CI 61.2%-67.4%)。
  • 倾向性评分匹配显示联合治疗未提高ORR,反而较单药治疗增加感染率。
  • 多因素分析显示联合治疗、III-IV级aGVHD及巴利昔单抗治疗前高危改良明尼苏达aGVHD风险评分与治疗反应独立相关。
  • 研究创建了可预测巴利昔单抗治疗后反应可能性降低风险的预后评分系统,并利用机器学习开发了在维持可接受感染风险水平下最大化巴利昔单抗疗效的方案。

关键数值与推荐

  • 第28天ORR累积发生率79.4%(95%CI 76.5%-82.3%)。
  • 3年非复发死亡率26.8%(95%CI 24.0%-29.6%),3年总生存率64.3%(95%CI 61.2%-67.4%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Steroid-refractory (SR) acute graft-versus-host disease (aGVHD) is one of the leading causes of early mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We investigated the efficacy, safety, prognostic factors, and optimal therapeutic protocol for SR-aGVHD patients treated with basiliximab in a real-world setting. Nine hundred and forty SR-aGVHD patients were recruited from 36 hospitals in China, and 3683 doses of basiliximab were administered. Basiliximab was used as monotherapy (n = 642) or in combination with other second-line treatments (n = 298). The cumulative incidence of overall response rate (ORR) at day 28 after basiliximab treatment was 79.4% (95% confidence interval [CI] 76.5%-82.3%). The probabilities of nonrelapse mortality and overall survival at 3 years after basiliximab treatment were 26.8% (95% CI 24.0%-29.6%) and 64.3% (95% CI 61.2%-67.4%), respectively. A 1:1 propensity score matching was performed to compare the efficacy and safety between the monotherapy and combined therapy groups. Combined therapy did not increase the ORR; conversely, it increased the infection rates compared with monotherapy. The multivariate analysis showed that combined therapy, grade III-IV aGVHD, and high-risk refined Minnesota aGVHD risk score before basiliximab treatment were independently associated with the therapeutic response. Hence, we created a prognostic scoring system that could predict the risk of having a decreased likelihood of response after basiliximab treatment. Machine learning was used to develop a protocol that maximized the efficacy of basiliximab while maintaining acceptable levels of infection risk. Thus, real-world data suggest that basiliximab is safe and effective for treating SR-aGVHD.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Mo XD, Hong SD, Zhao YL, et al. Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis. Am J Hematol. 2022. PMID: 35064928. doi:10.1002/ajh.26475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。